Diabetic Retinopathy (DR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Diabetic Retinopathy (DR) Market Outlook

Thelansis’s “Diabetic Retinopathy (DR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Retinopathy (DR) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Retinopathy (DR) Overview

Diabetic retinopathy (DR) is a microvascular disorder affecting the retina and arises as a complication of diabetes. It is linked to concurrent microvascular alterations in the brain, heart, kidneys, and peripheral nerves. The symptoms of this condition encompass blurred vision, sudden occurrences of dark “floaters” in the visual field, fluctuating vision, and the emergence of dark or empty patches in one’s vision. The likelihood of developing diabetic retinopathy hinges on the duration and type of diabetes mellitus. In instances where type 1 diabetes persists for 15 years or more, the risk escalates to 98%, while for type 2 diabetes with a similar duration, the risk reaches 78%. The precise mechanisms through which elevated blood sugar levels lead to diabetic retinopathy’s development and the visible histopathological alterations still require complete clarification. Diabetic retinopathy is categorized into nonproliferative and proliferative forms, contingent on the presence or absence of ocular neovascularization. Nonproliferative diabetic retinopathy (NPDR) is typified by anomalies in the retinal vasculature, including microaneurysms, intraretinal hemorrhages, venous beading, cotton wool spots, hard exudates, capillary nonperfusion, and macular edema. Individuals with diabetic retinopathy experience the emergence of permeable and leaky blood vessels that impact the light-sensitive photoreceptor layer at the rear of the eye. Treating diabetic retinopathy involves laser photocoagulation (PR) or the administration of steroids.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Diabetic Retinopathy (DR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034